HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Repeated Violations’ Close Door On Utah Supplement Marketer And Contract Manufacturer

Executive Summary

Consent decrees in federal court come four years after FDA warned both Evig and Premium Production about noncompliant claims for Evig’s Balance of Nature brand supplements and GMP violations at Premium’s plant.

You may also be interested in...



Marketer Of Glycerin, Oleate OTC Contraceptive Cream Consents To Ending Production, Sales

Smart Women’s Choice agrees to consent decree requiring it to halt production and sales of namesake brand product promoted as being hormone-free and with claims including “immobilizing sperm” and “preventing fertilization.” Related company with similar name, product and claims continues sales.

Glycerin, Oleate Cream Marketed Under Different Brand Still Not Approved As OTC Contraceptive

“Wise Women’s Choice, formerly known as Smart Women’s Choice contraceptive cream is 99.8% effective,” FDA reports finding on firm’s website.

FDA Warning Letter To Balance of Nature Cites Disease Claims On Supplements, GMP Violations

A February 2019 inspection of Balance of Nature’s manufacturing facility in St. George, UT, led FDA to claims on the firm's branded website and YouTube channel, which the agency says mark its products as unapproved drugs. Meanwhile, the site inspection turned up quality control and procedural documentation issues that still need to be resolved.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel